Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].
LOWELL, MA, May 2, 2018 – Rapid Micro Biosystems, the leading provider of automated, growth-based, rapid microbial detection technology for the healthcare product manufacturing sector, announced that it has secured $60 million in equity financing led by new investors Bain Capital Life Sciences and Xeraya Capital. The new funding round also includes a commitment from another new investor, Asahi...
EVANSTON, ILLINOIS, December 18, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline. The financing was led by Bain Capital Life Sciences. Additional new investors include Adage...
JENA, GERMANY, October 13, 2017 - InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today a $ 55M Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC and complemented by certain investment funds managed by a leading US investment...
NEW YORK, September 25, 2017 - SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its launch today with a completed $103 million Series A financing funded by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer (NYSE:PFE) and LifeArc (formerly known as...
WOBURN, MA, September 8, 2017 – Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP1, in multiple tumor types. The financing will also allow the Company...
CAMBRIDGE, MA, March 30, 2017 - Solid Biosciences announced today that it has completed the initial closing of its $50 Million Series C financing, which the company will use to progress its portfolio of programs targeted at Duchenne muscular dystrophy (DMD). The round was led by RA Capital Management and Bain Capital Life Sciences, together with funds from RTW Investments, Foresite Capital,...
CAMBRIDGE, MA, March 30, 2017 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) (the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a syndicate of current and new investors, led by Bain Capital Life Sciences, for the sale of redeemable convertible preferred stock...
Every student needs someone in their corner. Be that someone. Apply today @CityYear https://t.co/4YNgHHiuRt
[email protected] Corps member Stephanie shares five ways service with City Year has helped her grow.… https://t.co/DjCYukWxiU
First annual #JimmyFund5k and Fun Run is coming up July 22nd and will support the Jimmy Fund and @DanaFarber. https://t.co/lC6O1JIIOl
[email protected] is now accepting final applications for 2018-19 school year! Start your application today:… https://t.co/ldc7IlXihn
Rachel has ridden the Pan-Mass Challenge with her father for 6 years after losing a close family friend to cancer.… https://t.co/iI175Tv9jC
[email protected] is seeking planning committee members for their annual Pie in Sky fundraiser. Committee Kickoff Par… https://t.co/E79TsTuoWi
AmeriCorps members from @CityYearSanJose brush up on their resumes and practice professional skills with @BainCapVC… https://t.co/MDU9oqRtaD
A #gapyear that gives back: @CityYear! Apply today. https://t.co/4YNgHHiuRt https://t.co/opCdk3YA7S
"If he can believe in himself as much as I believe in him, he can blaze a path to new frontiers for himself and his… https://t.co/MMYtwfVrDQ